HEPATOCELLULAR CARCINOMA

This study tested a combination of two immunotherapy drugs, relatlimab and nivolumab, in 266 adults with advanced liver cancer who had not received immunotherapy before but had already tried other treatments. The goal was to see if the combination could shrink tumors and control …

This study tested whether giving radiotherapy to spots where liver cancer is growing can delay the need for switching to stronger second-line drugs. 36 adults with advanced liver cancer that had started to progress on first-line treatment received targeted radiation. The goal was…

This study tested a new treatment for people with advanced liver cancer that has spread into the major blood vessels of the liver. The treatment combines a special type of radiation (moderate-dose hypofractionated radiotherapy) with an immunotherapy drug called tislelizumab. The …

This study tested two immunotherapy drugs, nivolumab and ipilimumab, alone or together, in 657 adults with advanced liver cancer that could not be treated with surgery. The goal was to see if these drugs could shrink tumors and control the disease. Participants received different…

This study tested a combination of two drugs—SHR-1210 (an immunotherapy) and apatinib (a targeted therapy)—in 190 adults with advanced liver cancer that had not responded to or could not tolerate prior treatment. The goal was to see if the combo could shrink tumors and control th…

This study tested the drug pembrolizumab (an immunotherapy) against a placebo in 959 people with liver cancer who had no signs of cancer after surgery or local ablation. The goal was to see if the drug could delay or prevent the cancer from coming back and help people live longer…

This study tested a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), immunotherapy (PD-1/PD-L1 inhibitors), and targeted drugs (VEGF-TKI or bevacizumab)—in over 1,200 people with advanced liver cancer that had spread. The goal was to see if …

This study tested if somatostatin, a drug that lowers blood pressure in the liver, can prevent dangerous fluid buildup after liver cancer surgery. 179 patients with liver cancer and underlying liver disease took part. The goal was to see if the drug reduces the need for drainage …

This study tested a three-drug combination for people with advanced liver cancer that has spread into the portal vein. The treatment adds a direct liver chemo infusion to two standard drugs (lenvatinib and a PD-1 inhibitor). 66 patients took part to see if the triple therapy work…

This study tested a combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib in 344 people with advanced liver cancer who had not received prior treatment. The goal was to see if the combo helped patients live longer or shrink tumors more effectively. …

This study tested a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), immunotherapy (PD-1/PD-L1 inhibitors), and targeted drugs (VEGF-TKI or bevacizumab)—in 941 people with intermediate-stage liver cancer. The goal was to see if this triple t…

This study tested a new drug called SAR444245 (THOR-707) combined with other cancer treatments in 138 adults with advanced or metastatic gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancers. The goal was to see if the combination could shrink tum…

This study tested a new way to make radiation therapy work better for people with liver cancer. Doctors used special ultrasound contrast agents (tiny gas-filled microbubbles) and then 'popped' them with ultrasound waves to make tumors more sensitive to the radiation. The goal was…

This study looked at 74 adults with liver cancer that could not be surgically removed at first. After they received a combination of treatments (like chemoembolization, targeted therapy, and immunotherapy), some patients had their tumors completely disappear on scans. The study t…

This study tested a new way to treat small liver cancer using microwave ablation with two antennas at once, instead of the usual single antenna. Twenty adults with early-stage liver cancer took part. The goal was to see if the two-antenna method could completely destroy the tumor…

This early-stage study tested a new drug called CHS-388 in 145 people with advanced solid tumors (like kidney, liver, or lung cancer) that had stopped responding to standard treatments. The drug works by blocking a protein called IL-27 to help the immune system fight cancer. The …

This study looked at a flexible dosing method for delivering tiny radioactive beads (Y90 SIR-Spheres) directly to liver tumors that cannot be surgically removed. The goal was to see how well this approach controls the cancer and affects survival. Only one person took part, so res…

This study tested a new way to deliver chemotherapy directly to liver tumors by going through an artery in the wrist instead of the groin. 38 adults with liver cancer that could not be removed by surgery took part. The goal was to see if this approach is safe, works well, and hel…

This study tested whether combining two procedures—TACE (a chemo-blocking treatment) and RFA (a heat-based ablation)—works better than TACE alone for people with intermediate-stage liver cancer. 241 participants were randomly assigned to one of the two groups. The main goal was t…

This study tested a drug called PRL3-ZUMAB in 14 adults with advanced solid tumors (including stomach and liver cancers) that had stopped responding to standard therapies. The drug was given intravenously every two weeks. The goal was to see if it could shrink tumors or stop them…

This study tested a new drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. The drug targets two proteins (PD-1 and VEGF) to help the immune system fight the cancer and cut off its blood supply. The main goals were to see if the drug is…

This study tested whether adding a new drug called SRF388 to standard treatment (atezolizumab and bevacizumab) helps people with advanced liver cancer live longer without their cancer growing. Thirty adults who had not received prior treatment for their advanced liver cancer took…

This study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy given directly into the liver artery for people with advanced liver cancer that has spread into the main portal vein. The goal was to see if this treatment could help patients live longer. The …

This study tested two chemotherapy drugs, cisplatin and mitomycin-C, given directly into the liver artery for people with liver cancer that cannot be surgically removed. The goal was to see how long it takes for tumors to grow and to monitor side effects. The study also looked at…

This study tested a precise type of radiation called stereotaxic radiotherapy (CyberKnife) in 44 adults with early-stage liver cancer that could not be treated with standard methods. Participants received three high-dose radiation sessions over 8 to 10 days. The main goal was to …

This study looked at 150 people with both hepatitis C and a history of liver cancer that was successfully treated. They received new, interferon-free drugs to cure the hepatitis C virus. The main goal was to see if the virus stays gone 12 weeks after treatment, and also to check …

This study tested an improved radiofrequency ablation (heat treatment) method for liver cancer that came back after a prior procedure. One hundred adults with recurrent tumors received the treatment, and researchers tracked how many had tumor regrowth at the treated spot over two…

This early-phase study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. The study is now complete, but results are not yet …

This study looked at how safe the drug cabozantinib is for adults with advanced liver cancer (HCC) who had already tried another drug called sorafenib. A total of 110 participants were followed to track side effects and overall survival. The goal was to see if cabozantinib can be…

This study tested a new treatment for advanced liver cancer that has spread into the main vein of the liver. 63 patients received proton beam radiation to the tumor, followed by a combination of two drugs: atezolizumab (Tecentriq) and bevacizumab (Avastin). The goal was to see if…

This early-stage study tested a combination of two drugs (donafinib and an anti-PD-1 antibody) in 30 liver cancer patients at high risk of their cancer returning after surgery. The goal was to see if the treatment is safe and can help prevent recurrence within the first year. Whi…

This study tested a combination of two drugs, telatinib and Keytruda, in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see if the combo could slow cancer growth or improve survival. Participants had already tried other treatments wit…

This study explored whether a breath test could help find liver scarring (fibrosis), severe scarring (cirrhosis), or liver cancer early. Researchers collected breath samples from 56 adults with known or suspected liver problems. They used special machines to look for unique chemi…

This study tested a new imaging agent called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The goal was to see if this PET scan could better detect cancer cells compared to standard methods. Resear…

This study tested a new imaging method that uses a radioactive tracer (68Ga-PSMA) with PET/MRI or PET/CT scans to find liver cancer earlier and stage it more accurately. About 52 adults with liver cancer took part. The goal was to see if this approach works better than standard s…

This study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer in people with hepatitis C. Researchers tested 84 participants, including healthy people and those with hepatitis C, liver cirrhosis, or liver cancer. They found tha…

This study looked at how well two different treatments work in real life for people with advanced liver cancer and cirrhosis. Researchers compared a combination of two drugs (Atezolizumab and Bevacizumab) to a group of similar patients who took a different type of drug (tyrosine …

This study looked at tumor and blood samples from 166 people with advanced liver cancer to find genetic markers that might predict how well they respond to treatment. The goal was to better understand the disease and identify new targets for therapy. Participants had already rece…

This study involved 17 adults with liver cancer who were scheduled for standard treatments like TACE or ablation. Researchers took blood samples before and after treatment to look for proteins that might predict survival and tumor response. No experimental treatment was given—the…

This study looked at whether liver cancer spreads differently in men and women. Researchers analyzed data from over 19,000 patients and used machine learning to create separate prediction tools for each gender. The goal was to better understand which factors predict cancer spread…

This study looked at the genetic makeup of liver cancer in 808 patients. The goal was to find common gene changes and patterns that could help doctors better understand the disease. Researchers used tumor samples from patients who had surgery or other treatments. The results may …

This study reviewed medical records of 300 liver cancer patients in Brazil to understand their health history, treatments, and outcomes. It did not test any new drug or therapy. The goal was to gather real-world information to help doctors better manage the disease.

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…

This study looked at how often the EchoTip AcuCore biopsy needle successfully gets a tissue sample during endoscopic ultrasound procedures. It included 183 adults with various conditions like cancer or pancreatitis. The goal was to gather real-world information on the device's pe…